Profile cover photo
Profile photo
Renal & Urology News
219 followers -
Clinical news for nephrologists and urologists.
Clinical news for nephrologists and urologists.

219 followers
About
Renal & Urology News's posts

Post has attachment
Neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) may provide a survival advantage for patients with neuroendocrine tumors of the bladder, researchers revealed at the American Urological Association 2017 annual meeting. Get the details:

Post has attachment
Over the last decade, multiparametric MRI-transrectal ultrasound (mpMRI-TRUS) fusion biopsy has improved detection of clinically significant prostate cancer (PCa) of Gleason score 3+4 and higher while reducing overdetection of low-risk disease, according to researchers presenting at the American Urological Association 2017 annual meeting. Learn more:

Post has attachment
Check out our extensive coverage of the American Urological Association's 2017 meeting in Boston for the latest clinical updates in urology. http://ow.ly/8luL30bJp1d
Photo

Post has attachment
Read through our coverage of the American Transplant Congress 2017, featuring the latest information in the field of transplant science.

Post has attachment
Check out our video on preventing and managing hepatitis C in chronic kidney disease patients at various stages.

Post has attachment
Voclosporin, a novel calcineurin inhibitor, is significantly more effective than placebo at achieving rapid complete and partial remission of active lupus nephritis, according to 48-week phase 2b study data.

Post has attachment
Check out Renal & Urology News' live coverage of the 2017 NKF Spring Clinical Meetings in Orlando for the latest research insights.

Post has attachment
Tolvaptan treatment has a sustained disease-modifying effect on estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD). Learn more:

Post has attachment
In this first of a series of Ask the Experts features, Renal & Urology News presents separate interviews with two prominent researchers, Tomasz M. Beer, MD, http://ow.ly/nUs830aFc0f and E. David Crawford, MD, http://ow.ly/bLzT30aFbz who discuss their experiences with the new medications for metastatic castration-resistant prostate cancer (mCRPC).

Post has attachment
Family history of prostate cancer is unlikely to be a reason to exclude men from active surveillance for low-risk PCa. Learn about the latest research:
Wait while more posts are being loaded